Oxford BioMedica

  www.oxfordbiomedica.co.uk
  www.oxfordbiomedica.co.uk
Work in HR? Unlock Free Profile

Oxford BioMedica Reviews

2 Reviews
3.0
2 Reviews

Recommend to a friend
Approve of CEO
Oxford BioMedica CEO and Director John Dawson
John Dawson
0 Ratings
  1.  

    Exiting prospects.

    Former Employee - Anonymous Employee
    Former Employee - Anonymous Employee

    I worked at Oxford BioMedica

    Pros

    Great people and facilities. Exciting product pipeline from many angles. Takes time out to celebrate and reward staff. Opportunity to work on genuinely important and interesting topics of your into bioscience and biomanufacturing.

    Cons

    Quite a lot of bureaucracy. No real onboarding structure other than basic health and safety. Management not transparent. Slow pace of work. I didn't personally connect with the culture there but others seemed to enjoy the atmosphere.

    Advice to ManagementAdvice

    If you want to recruit and retain talent invest in people early, give them exciting work and provide some useful structure. Otherwise you're self selecting hires who will put up with average performance and slow progress.

Oxford BioMedica Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Edit Profile
Website www.oxfordbiomedica.co.uk
Headquarters Oxford, United Kingdom
Size 50 to 149 Employees
Founded Unknown
Type Company - Public (OXB)
Industry Biotech & Pharmaceuticals
Revenue $10 to $25 million (USD) per year

Oxford BioMedica has no reservations about launching attacks on disease. The biotechnology company uses gene therapy and immunotherapy to develop treatments for cancer, as well as neurodegenerative and ocular diseases. Its four ocular gene therapies are partnered with Sanofi; the company works with Pfizer on another targeted antibody therapy. The company has three lead products: TroVax, ProSavin, and RetinoStat (being developed with Sanofi). TroVax is in late-stage clinical trials for the treatment of prostate cancer. ProSavin is being tested to treat Parkinson's disease... More

Worked for Oxford BioMedica? Contribute to the Community!